The Evolving Role of NGS and Measurable Residual Disease in CLL/SLL and AML

While diagnostic test procedures are well defined for hematologic malignances, despite the scientific communities’ recognition of its importance, guidelines for IGHV somatic hypermutation (SHM) status and MRD remain ambiguous. Recent advancements in next-generation sequencing (NGS) have led to improved classifications for inclusion in clinical trials, determination of prognosis, and improved treatments. A growing body of research suggests that the presence of any MRD, particularly in AML, provides important information regarding risk for subsequent relapse. Lastly, we will discuss best practices for the detection of specific genetic mutations, such as mutated IGHV in CLL/SLL.